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Abstract
Purpose Evidence is conflicting on the prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)
in head and neck squamous cell carcinoma. The aim of our study was to determine the impact of semiquantitative and qualitative
metabolic parameters on the outcome in patients managed with standard treatment for locally advanced disease.
Methods A systematic review of the literature was conducted. A meta-analysis was performed of studies providing estimates of
relative risk (RR) for the association between semiquantitative metabolic parameters and efficacy outcome measures.
Results The analysis included 25 studies, for a total of 2,223 subjects. The most frequent primary tumour site was the oropharynx
(1,150/2,223 patients, 51.7%). According to the available data, the majority of patients had stage III/IV disease (1,709/1,799,
94.9%; no information available in four studies) and were treated with standard concurrent chemoradiotherapy (1,562/2,009
patients, 77.7%; only one study without available information). A total of 11, 8 and 4 independent studies provided RR estimates
for the association between baseline FDG PET metrics and overall survival (OS), progression-free survival (PFS) and locoregional
control (LRC), respectively. High pretreatment metabolic tumour volume (MTV) was significantly associated with a worse OS
(summary RR 1.86, 95% CI 1.08–3.21), PFS (summary RR 1.81, 95% CI 1.14–2.89) and LRC (summary RR 3.49, 95% CI 1.65–
7.35). Given the large heterogeneity (I2 > 50%) affecting the summary measures, no cumulative threshold for an unfavourable
prognosis could be defined. No statistically significant association was found between SUVmax and any of the outcome measures.
Conclusion FDG PET has prognostic relevance in the context of locally advanced head and neck squamous cell carcinoma.
Pretreatment MTV is the only metabolic variable with a significant impact on patient outcome. Because of the heterogeneity and
the lack of standardized methodology, no definitive conclusions on optimal cut-off values can be drawn.
Keywords Head and neck cancer . Radiotherapy . 18F-Fluorodeoxyglucose (FDG) positron emission tomography . Metabolic
tumour volume
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Introduction
Head and neck cancer is the sixth most common malignant
tumour, with increasing incidence worldwide [1]. In over 95%
of cases, the disease arises from the epithelial layer of the
mucosa lining the upper aerodigestive tract. Due to the ab-
sence of anatomical barriers, the abundant lymphatic drainage
of the neck and the usually infiltrative pattern of growth of
head and neck squamous cell carcinoma (HNSCC), in about
60% of patients the diagnosis is made at an advanced
locoregional stage. In order to maximize the likelihood of
disease cure, multimodality treatment is usually needed.
Therapeutic management is often challenging: both primary
radical surgery and concurrent chemoradiotherapy are bur-
dened with a high rate of posttreatment complications, acute
and long-term toxicities [2] and amarked detrimental effect on
quality of life. Notwithstanding the refinement of treatment
strategies that has taken place in last 20 years, the prognosis
of HNSCC remains severe, with a cumulative 5-year overall
survival (OS) rate of 45–55% [3] in patients with locally ad-
vanced disease. The prevalent pattern of failure in the overall
population is locoregional: about 50% of first events of relapse
occur at the primary tumour site and/or in the neck, in the vast
majority (about 90%) within the first 2 years after treatment.
Taking into account that the patient’s outlook can be sub-
stantially influenced by clinical factors with large variability
existing among the different subsites of disease, a series of
common features contribute to the severe prognosis of locally
advanced HNSCC; these include the suboptimal efficacy of
the standard Bone size fits all^multimodal approach, the large
proportion of frail patients who are noncompliant with inten-
sive therapy, and the absence of biomarkers. In this regard, the
only notable exception is the human papillomavirus (HPV). In
the last 15 years, a major epidemiological shift has taken place
in western countries due to the rising incidence of HPV-
associated oropharyngeal cancer [4], reducing the dominance
of the classical phenotype of HNSCC resulting from alcohol
and tobacco-induced field cancerization. A positive HPV sta-
tus was recognized as an independent favourable prognostic
factor in a series of correlative prospective studies and in an
unplanned secondary analysis of the randomized phase 3
RTOG 0129 trial [5]. Overall, HPV positivity is associated
with a reduction in the risk of death and disease progression
of about 60%.
Although major progress has been achieved in unravelling
key molecular pathways involved in HNSCC pathogenesis
[6], at present no biomarkers are available in clinical practice
apart from HPV status. Prognostic information is therefore
critically lacking in the management of patients affected by
HNSCC. Next to individual genomic profiling, an alternative
strategy which has been explored in recent years is to integrate
molecular imaging into precision oncology care, exploiting
the potential of imaging as a biomarker. The possibility of
linking the information obtained from medical images with
personalized treatment forms the core of Btheragnostics^, an
term that has been used particularly in the context of radiation
therapy [7]. In a hallmark review published in 2000, Ling et al.
[8] suggested that the evolution of molecular imaging could
facilitate the development of customized dose delivery in the
era of intensity-modulated radiotherapy (IMRT). As foreseen
by Ling and colleagues, in the last 15 years molecular imaging
has been increasingly implemented in the management of
HNSCC, in particular 18F-fluorodeoxyglucose (FDG) posi-
tron emission tomography (PET). The fundamental prerequi-
site is the ability to image physiopathological processes oc-
curring within a tumour or its microenvironment. The use of
FDG allows the characterization of the metabolic activity of a
defined tumour burden. In HNSCC, available evidence sup-
ports the role of FDG PET in primary target definition for
radiotherapy planning [9], staging [10] and posttreatment re-
sponse assessment [11]. However, its potential impact on pa-
tient outcomes is an unresolved issue. The aim of this work
was to define the relevance of semiquantitative and qualitative
FDG PET features as prognostic biomarkers in the curative
setting of locally advanced head and neck cancer.
Materials and methods
In accordance with the PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses) statement [12], a
systematic review of the literature was conducted. Relevant
articles were identified in two databases (MEDLINE and
Embase) over a 10-year period (1 January 2007 to 28
February 2017) using the appropriate terminology as de-
scribed in Appendix 1 of the Supplementary material.
Conference proceedings of main international conferences
(ASCO, ASTRO, ESMO, ESTRO, ECCO) were also
searched. The reference lists of the articles reviewed as full
texts were also searched manually. The literature search strat-
egy was based on the PICOmethodology [13], as discussed in
the following sections.
Population
The target population of our analysis consisted of adult
patients (>18 years of age) treated with curatively intended
radiotherapy, concurrent chemoradiotherapy or radiotherapy
combined with targeted therapy for locally advanced
HNSCC. Primary surgery and induction chemotherapy
were not allowed. In view of the known heterogeneity
among different head and neck subsites, we sought to
assess whether the impact of metabolic parameters could
be observed in specific disease entities or in HNSCC tak-
en as a whole. In addition, information on the radiothera-
py technique used and the schedule of systemic therapy
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administered was collected when available. To provide
evidence-based support for the analysis, the published lit-
erature was categorized according to the type of study
design: all case series except those with fewer than 20
patients, literature reviews and consensus statements were
eligible. Only studies in the English language were
included.
Interventions
Upon inclusion in the analysis, adequate information on FDG
PET metrics (semiquantitative parameters and/or qualitative
scores) had to be retrieved from the studies analysed.
Studies focusing on tracers other than FDG and on integrated
PET/MRI were excluded. Since the main aim of this review
was to investigate the potential impact of specific metabolic
data on HNSCC prognosis, the following parameters were
considered as main interventions: standardized uptake values
(SUVmax, SUVmean, SUVpeak), metabolic tumour volume
(MTV) and total lesion glycolysis (TLG). These parameters
were defined according to reference guidelines [14], as
follows:
– SUV (body-weighted): the concentration of FDG in a
given region of interest (ROI) or volume of interest
(VOI; expressed in kilobecquerels per millilitre) divided
by the ratio between administered activity (corrected for
radioactive decay at the time of scanning) and the body
weight of the patient
– SUVmax: the highest SUVof pixels (or voxels) in a given
ROI (or VOI)
– SUVmean: the mean SUVof pixels (or voxels) in a given
ROI (or VOI)
– SUVpeak: SUVmean within a 1-cm
3 spherical VOI centred
on the voxels with the highest uptake
– MTV: the VOI segmented using a fixed threshold (usual-
ly 41% or 50%) of FDG-avid lesions
– TLG: the product of the VOI average SUV (SUVmean)
and the corresponding MTV
Standardized qualitative interpretations of FDG PET scans
were also considered interventions, if rigorously defined. In
addition, the included studies were further analysed according
to the timing of the FDG PET scans, whether performed be-
fore, during or after treatment.
Comparators
When available, different clinical factors other than the meta-
bolic FDG PET parameters discussed above were defined as
Bcomparators^ if analysed as potential prognostic biomarkers.
Outcomes
Ultimately, we sought to assess whether intrinsic features on
FDG PET retain prognostic significance in terms of outcome.
Therefore, we searched for a potential correlation between the
interventions (as described above) and locoregional control
(LRC), progression-free survival (PFS) and OS at a minimum
follow-up of 1 year. These outcome measures were defined as
follows:
– LRC: the time from randomization (or study initiation) to
local and/or regional disease progression
– PFS: the time from randomization (or study initiation) to
disease progression or death
– OS: the time from randomization (or study initiation) to
death from any cause
Studies in which the main outcome measure was not con-
sistent with the definition of the prespecified efficacy end-
points were excluded. Studies performed to assess the diag-
nostic accuracy of FDG PET as well as Bin-silico^ radiother-
apy planning analyses were also excluded.
Statistical analysis
Baseline demographics, patient and disease characteris-
tics, treatment features and outcome data were collected
by three authors (P.B., A.M., E.O.), verified by two re-
viewers (I.D., S.C.) and summarized using descriptive
statistics. From all studies included in the literature re-
view, we extracted the most adjusted estimate of relative
risk (RR), including odds ratio and hazard ratio (HR), for
the association between each of the metabolic parameters
(SUVmax, SUVmean, SUVpeak, MTV and TLG) and each of
the patient outcomes (OS, PFS and LRC). When there
were two or more independent RR estimates, these were
transformed into logRR and the corresponding variance
using the formula of Greenland [15] and pooled using
random effects models to obtain a summary RR (SRR)
and corresponding 95% confidence intervals (CI). We
assessed the heterogeneity between studies using the I2
statistic, which is interpreted as the percentage of the var-
iability that is attributable to true heterogeneity rather than
chance. Larger values of I2 denote greater between-
estimate heterogeneity; values of I2 below 50% are con-
sidered acceptable. We did not perform subgroup analysis
and meta-regression because of the limited sample size.
Finally, we evaluated the presence of publication bias
using the funnel plot of Begg and Mazumdar [16] and
the regression test of Egger et al. [17]. The meta-
analysis was conducted using the metan command in
Stata version 14 (Stata Corp, College Station, TX).
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Results
Data collection and analysis
Two authors (P.B., A.M.) independently examined the titles
and abstracts of each search record, and retrieved the full text
articles for potentially eligible studies. The full texts were
further examined according to the inclusion criteria.
Discrepancies were resolved by consensus. Data were extract-
ed by the two authors using a data collection form. Overall, of
180 studies identified using the predefined search criteria, 81
were screened by assessment of the abstracts (Fig. 1). Of these
screened studies, 42 were evaluated for eligibility, and 25
[18–44] satisfied the inclusion criteria and were therefore
analysed fully. The whole reference lists of the eligible studies
and the reasons for exclusion are available in Appendix 2 of
the Supplementary material. In terms of study design, most
included studies (21/25, 84%) were retrospective. Two papers
were initially retrieved in abstract form [33, 41] and updated
as soon as the full versions became available [34, 42]. One
study [29] had limited data on the disease and treatment char-
acteristics collected in most patients, but provided adequate
information on FDG PET variables and outcomes.
Patient characteristics
The overall population consisted of 2,223 patients (Table 1).
The median age of the whole cohort was 59 years (range 48–
68 years). Most patients (1,875/2,223, 84.3%) were men.
Only 3 of the 25 studies [31, 32, 40] provided information
about tobacco exposure in terms of pack-years. Generic infor-
mation on subjects with a smoking history was reported in six
additional studies [22, 28–30, 39, 43] (81.4%, 82.6%, 67.3%,
80%, 90.9% and 72% of patients were current or former
smokers, respectively). In addition, data on baseline ECOG
Performance Status were reported for only 29% of the whole
cohort (646/2,223).
Disease-related features
The most frequent primary tumour site was the oropharynx
(1,150/2,223 patients, 51.7%), followed by the hypopharynx
(377, 16.9%), larynx (345, 15.6%), nasopharynx (197, 8.9%),
oral cavity (98, 4.4%), and others (56, 2.5%; Table 2).
Information on HPV status was available for fewer than half
of those with oropharyngeal tumour (508/1,150, 44.1%), and
of these (as extrapolable from 7 of the 25 studies) 247 (48.6%)
were p16/HPV-positive. Overall, in the majority of patients
(1,709/1,799, 94.9%; no information available in four studies)
the disease was in aggregated stage III/IV (Table 3).
Treatment-related features
Most patients (1,467/1,544, 95%) were treated with IMRT,
while 77 (5%) received 3D-conformal radiotherapy
(3DCRT). No information on the radiotherapy technique used
was available in seven studies (Table 4). The most adopted
radiotherapy regimen consisted of conventional fractionation
of 1.8 or 2 Gy per fraction for a total dose of 66–72 Gy in the
majority of cases (22/23 papers; no available data in two stud-
ies). Concurrent chemoradiotherapy was the most frequent
treatment schedule in our analysis, being used in 1,562/
2,009 patients (77.7%; no available information in only one
study). Standard three-weekly 100 mg/m2 cisplatin was the
chosen regimen in almost half of the included studies (11/
24). Finally, a very small group of patients received induction
chemotherapy before radiotherapy (181/2,223, 8.1%) in seven
studies. On the basis that these studies were not excluded by
our entry search criteria, they were retained in the analysis.Fig. 1 Flow chart of the literature search
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Prognostic impact of FDG PET: descriptive analysis
The timing of FDG PET was different among the studies in-
cluded in the analysis (Table 5). A single baseline assessment
time-point was present in almost half of the studies (12/25)
while a combination of pretreatment, interim (during treat-
ment) and posttreatment scans was described in four (pretreat-
ment plus interim), seven (pretreatment plus posttreatment)
and two (pretreatment plus interim plus posttreatment) studies.
Among those studies providing data on more than a single
time-point, a time-weighted analysis exploring changes over
time (Bdelta^) of specific metabolic semiquantitative or quali-
tative features was additionally reported in seven. As a single
variable, MTVand SUVmax were the main metabolic parame-
ters addressed in nine and seven studies, respectively. A qual-
itative analysis was used in three studies [29, 31, 42]. Zschaeck
et al. [44] determined SUVmean in irradiated normal mucosa
tissue to explore the impact of off-target hypermetabolism and
its change over time. Only a limited number of alternative
prognostic biomarkers (comparators) were reported in parallel
with the metabolic evaluation (nine studies). The median over-
all follow-up time for all studies was 23.6 months (range 15–
55.8 months). In terms of threshold or cut-off values to dis-
criminate worse from better outcomes, a large variability was
observed for each intervention. Finally, a large heterogeneity
characterized the prognostic information which could be ex-
tracted from each paper.
Prognostic impact of pretreatment FDG PET:
meta-analysis
A total of 11 [20–22, 25, 34–37, 40, 43, 45], 8 [20–23, 35, 36,
38, 40] and 4 [21, 25, 37, 40] independent studies provided
RR estimates for the association between baseline FDG PET
and OS, PFS and LRC, respectively. These studies were thus
included in the meta-analysis aiming to assess the potential
Table 1 Design of the studies analysed and patient characteristics
Reference Year Study design Patient characteristics
Total number Age (years) Gender, n (%) Smoking
(pack-years)
ECOG performance
status, grade (%)
Median Range Male Female
[18] 2015 Retrospective 62 57 23–83 44 (71) 18 (29) ns ns
[19] 2012 Retrospective 26 63 41–79 23 (89) 3 (11) ns ns
[20] 2017 Retrospective 122 61 ns 101 (83) 21 (17) ns ns
[21] 2014 Prospective 51 52 36–69 48 (94) 3 (6) ns ns
[22] 2013 Retrospective 70 52 37–86 66 (94) 4 (6) ns ns
[23] 2009 Retrospective 82 53.8 11–70 69 (84) 13 (16) ns ns
[24] 2012 Retrospective 88 59 26–83 74 (84) 14 (16) ns ns
[25] 2015 Retrospective 70 65 21–91 61 (87) 9 (13) ns ns
[26] 2016 Retrospective 78 62 24–79 63 (81) 15 (19) ns 0/1 (98.8)
[27] 2014 Retrospective 108 67 43–85 93 (86) 15 (14) ns ns
[28] 2017 Retrospective 75 59 39–80 67 (89) 8 (11) ns ns
[29] 2014 Retrospective 214 58 ns 175 (82) 39 (18) ns ns
[30] 2017 Prospective 35 67.6 50–80 32 (91) 3 (9) ns 0/1 (100)
[31] 2016 Retrospective 69 61 39–81 61 (88) 8 (12) >10: 40 (60.9%) ns
[32] 2015 Retrospective 72 60 39–75 61 (85) 11 (15) >10: 41 (56.9%) ns
[34] 2017 Retrospective 85 66 43–79 81 (95) 4 (5) ns ns
[35] 2011 Retrospective 47 55.1 15–86.1 39 (83) 8 (17) ns 0/1 (95)
[36] 2016 Prospective 86 50 40–60 80 (93) 6 (7) ns ns
[37] 2013 Retrospective 81 65 34–81 74 (91) 7 (9) ns ns
[38] 2015 Retrospective 287 64 33–89 221 (77) 66 (23) ns 0 (63)
[39] 2014 Retrospective 100 56 27–81 86 (86) 14 (14) ns ns
[40] 2015 Prospective 74 56 42–73 65 (88) 9 (12) 8.75 (median) 0/1 (100)
[42] 2016 Prospective 125 59 ns 93 (74) 32 (26) ns 0/1 (100)
[43] 2014 Retrospective 40 48 21–69 30 (75) 10 (25) ns ns
[44] 2017 Retrospective 76 55 42–76 68 (89) 8 (11) ns ns
ns not stated
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prognostic impact of pretreatment metabolic features on pa-
tient outcome. Of note, Castelli et al. [45] performed a sec-
ondary analysis in the same patient population analysed in a
previous work [20] providing additional data with distinct RR
estimates that were therefore worthy of inclusion. Instead, the
results reported by Zschaeck et al. [44] were not considered,
since the prognostic value of uptake in mucosa soft tissue was
not investigated in any of the other included studies. In terms
of baseline FDG PET parameters, the analysis was limited to
MTV and SUVmax, for which there were six and seven RR
estimates for OS (Figs. 2 and 3), three and seven for PFS
(Figs. 4 and 5), and two and three for LRC (Figs. 6 and 7),
respectively. Higher MTV values for the primary or primary
and nodal disease combined were significantly associated
with a worse OS (SRR 1.86, 95% CI 1.08–3.21), PFS (SRR
1.81, 95% CI 1.14–2.89) and LRC (SRR 3.49, 95% CI 1.65–
7.35), Instead, we found no statistically significant association
between SUVmax and any of OS, PFS and LRC. Given the
large between-study heterogeneity (I2 > 50%) that affected the
summary measures, no effort was made to define a cumulative
threshold value for an unfavourable prognosis. Finally, apart
from an unclear or high risk of bias in terms of patient selec-
tion (21/25 studies, 84%) because of the predominantly retro-
spective nature of the included studies, according to the
QUADAS-2 tool [46] the overall quality was good with low
risks of bias and concerns regarding applicability in the re-
maining domains (Supplementary Table 6).
Discussion
In the era of precision oncology, the lack of prognostic bio-
markers has hindered the evolution of standard-of-care man-
agement in HNSCC. Apart from HPV status, no molecular
stratification is currently available for use in daily practice.
In the last two decades, steady technological progress has
highlighted the potential of imaging as a comprehensive tu-
mour biomarker [47]. In the field of functional imaging, FDG
PET is the most widespread, easily accessible modality that is
able to provide surrogate metabolic information on tumour
Table 2 Disease features: tumour site
Reference Number of patients Oropharynx Larynx Hypopharynx Oral cavity Nasopharynx Other
Total p16/HPV-positive
[18] 62 14 (22%) ns 10 (16%) 12 (20%) 3 (5%) 14 (22%) 9 (15%)
[19] 26 12 (46%) ns 9 (35%) 2 (8%) 0 3 (11%) 0
[20] 122 122 (100%) 32 (26%) 0 0 0 0 0
[21] 51 20 (39%) ns 0 21 (41%) 0 10 (20%) 0
[22] 70 70 (100%) 13 (19%) 0 0 0 0 0
[23] 82 13 (16%) ns 0 6 (7%) 0 63 (77%) 0
[24] 88 58 (66%) ns 15 (17%) 0 1 (1%) 7 (8%) 7 (8%)
[25] 70 25 (36%) ns 0 36 (51%) 0 9 (13%) 0
[26] 78 47 (61%) ns 3 (4%) 19 (24%) 5 (6%) 0 4 (5%)
[27] 108 28 (26%) ns 29 (27%) 34 (31%) 17 (16%) 0 0
[28] 75 56 (75%) ns 11 (15%) 5 (6%) 3 (4%) 0 0
[29] 214 135 (63%) 123 (57%) 40 (19%) 0 11 (5%) 0 28: (13%)
[30] 35 9 (26%) ns 11 (31%) 12 (34%) 3 (9%) 0 0
[31] 69 41 (59%) ns 20 (30%) 5 (7%) 3 (4%) 0 0
[32] 72 47 (66%) ns 16 (22%) 6 (8%) 3 (4%) 0 0
[34] 85 0 ns 35 (41%) 50 (59%) 0 0 0
[35] 47 21 (45%) ns 7 (15%) 4 (8%) 2 (4%) 13 (28%) 0
[36] 86 45 (52%) ns 0 41 (48%) 0 0 0
[37] 81 0 ns 57 (70%) 24 (30%) 0 0 0
[38] 287 129 (45%) ns 44 (15%) 55 (19%) 29 (10%) 30 (11%) 0
[39] 100 100 (100%) 14 (14%) 0 0 0 0 0
[40] 74 58 (78%) 25 (34%) 9 (12%) 7 (10%) 0 0 0
[42] 125 69 (56%) 37 (30%) 21 (17%) 11 (9%) 8 (6%) 8 (6%) 8 (6%)
[43] 40 0 0 0 0 0 40 (100%) 0
[44] 76 31 (41%) 3 (4%) 8 (10%) 27 (36%) 10 (13%) 0 0
ns not stated
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burden. The aim of our work was to define whether distinct
FDG PET features can be intrinsically associated with prog-
nostic relevance in the context of nonmetastatic HNSCC. We
acknowledge several limitations which have to be taken into
account when interpreting the data presented. First, most stud-
ies included in our systematic review were retrospective.
Although a strict search methodology was followed, their po-
tential heterogeneity in terms of patient selection, treatment
administration and outcome measures may have affected the
consistency of our analysis. Second, the technical variability
in the performance of FDG PET scans is also a factor that
cannot be ignored with a retrospective study design; only a
prospective design can ensure that consensus acquisition rec-
ommendations [14] are rigorously adopted. Third, among the
included studies the methods used to calculate the FDG PET
metrics were not consistent. Heterogeneity in their definition
has to be taken into account particularly for SUVmax and
MTV, for which several threshold values were shown to be
significant in discriminating patients with different outcomes.
Renewed interest in the role of FDG PET in the man-
agement of HNSCC was recently prompted by the
publication of the PET-NECK trial [11]. The findings of
this large prospective, multicentre phase 3 trial are prac-
tice-changing, since the study provided definitive evidence
in favour of a response evaluation centred on the high
negative predictive value (NPV) of a 12-week posttreat-
ment FDG PET scan. However, the study had two main
limitations that prevented the clarification of other relevant
issues on the role of FDG PET in the management of
HNSCC. First, none of the 564 patients enrolled in the
trial underwent a baseline FDG PET scan; a qualitative
comparison between pretreatment and posttreatment scans
was therefore not performed. Second, FDG PET semiquan-
titative metrics could not be evaluated due to nonuniform
calibration among the different scanners. From this per-
spective, the PET-NECK trial did not add any new data
to the available low-level body of evidence on the prog-
nostic role of specific FDG PET semiquantitative and
qualitative features in HNSCC. Although many investiga-
tors have focused on this topic in the last 15 years [48],
the literature is characterized by inconclusive and hetero-
geneous findings [49].
Table 3 Disease features: stage
Reference Tx T1 T2 T3 T4 N0 N1 N2 N3 I II III IV III/IV
[18] 0 8 20 14 20 ns ns ns ns 0 10 (16%) 18 (29%) 34 (55%) 52 (84%)
[19] 0 3 9 6 8 3 7 16 0 0 1 (3%) 7 (27%) 18 (70%) 25 (97%)
[20] 0 7 36 52 27 14 21 80 7 0 0 ns ns 122 (100%)
[21] ns ns ns ns ns ns ns ns ns 0 0 16 (31%) 35 (69%) 51 (100%)
[22] 0 0 0 20 50 ns ns ns ns 0 8 (11%) 43 (52%) 19 (27%) 62 (89%)
[23] 0 22 25 17 18 10 22 43 7 4 (5%) 12 (15%) 30 (36%) 36 (44%) 66 (80%)
[24] ns ns ns ns ns ns ns ns ns 3 (3%) 1 (1%) 15 (16%) 70 (80%) 85 (96%)
[25] 0 0 34 16 20 29 10 18 13 ns ns ns ns ns
[26] ns ns ns ns ns ns ns ns ns ns ns 23 (30%) 55 (70%) 78 (100%)
[27] 0 26 37 13 32 51 14 40 3 18 (17%) 20 (18%) 19 (18%) 51 (47%) 70 (65%)
[28] 0 6 31 27 11 0 11 59 5 0 0 10 (13%) 65 (87%) 75 (100%)
[29] ns ns ns ns ns ns ns ns ns ns ns ns ns ns
[30] 0 0 13 16 6 13 4 16 2 0 4 (11%) 10 (29%) 21 (60%) 31 (89%)
[31] 0 4 28 27 10 16 10 39 4 0 6 (9%) 18 (26%) 45 (65%) 63 (91%)
[32] 0 6 25 31 10 9 11 47 5 0 0 18 (25%) 54 (75%) 72 (100%)
[34] 0 0 19 49 17 26 15 44 0 0 0 33 (39%) 52 (61%) 85 (100%)
[35] ns ns ns ns ns ns ns ns ns 0 2 (4%) 11 (23%) 34 (73%) 45 (96%)
[36] ns ns ns ns ns ns ns ns ns 0 0 4 (5%) 82 (95%) 86 (100%)
[37] 0 2 11 43 25 28 15 38 3 0 0 32 (39%) 49 (61%) 81 (100%)
[38] 0 32 92 78 85 30 32 190 35 0 0 54 (19%) 233 (81%) 287 (100%)
[39] 0 14 39 23 24 4 12 80 4 ns ns ns ns ns
[40] 0 0 29 26 19 0 0 ns 6 0 0 ns ns 74 (100%)
[42] 7 ns ns ns ns 0 0 119 6 0 0 ns ns 125 (100%)
[43] 0 14 ns ns ns 0 19 ns ns 7 ns ns ns ns
[44] 0 2 10 27 37 12 7 54 3 1 (1%) 1 (1%) 11 (15%) 63 (83%) 74 (98%)
ns not stated
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A crucial aspect that needs again to be underlined is the
strict dependence of FDG PET information on the image ac-
quisitionmodality, which in turnmay be influenced by a series
of factors, ranging from the technical parameters of the scan-
ner to the timing of the scan with respect to treatment. As also
demonstrated in our descriptive analysis (Table 5), there is
significant variability in the correlation between semiquanti-
tative metrics and outcome measures in HNSCC. We have
already pointed out that in the posttreatment scenario a nega-
tive PETscan at 12 weeks after chemoradiation is a prognostic
biomarker of long-term complete remission based on level 1
evidence. However, standardized interpretation of response to
treatment is lacking. In this context, the Hopkins criteria are
the only proposed scoring system for qualitative interpretation
of FDGPET in HNSCC.Marcus et al. [29] showed that a five-
point scale based on prespecified qualitative descriptors is
accurate in discriminating complete from incomplete re-
sponses. The application of the Hopkins criteria resulted in a
high NPV of 91.1% with an overall diagnostic accuracy of
86.9%. Notably, the results of the ECLYPS study [42] pro-
spectively confirmed the reliability of the Hopkins criteria
applied 12 weeks after the end of treatment, with an overall
NPVof 92.1% and a very low number of equivocal reports. As
accurately described by Garibaldi et al. [50] in a recent sys-
tematic review, the potential prognostic and predictive rele-
vance of an interim FDG PET scan (scan acquired during
treatment) is a controversial matter. At present, no firm con-
clusions can be drawn as to the ideal metabolic parameter to
analyse early in treatment, the most informative threshold val-
ue, or the best time to re-scan the patient.
Taking all together, the use of FDG PET in patients with
HNSCC provides prognostic information through standard-
ized qualitative assessment at a minimum of 12 weeks after
chemoradiation, but no added value during its delivery. It is
therefore a rational approach to investigate before treatment
whether baseline semiquantitative metrics are intrinsically
able to characterize the outcome in patients with locally ad-
vanced disease. Conflicting evidence is available from the
literature. Pak et al. [51] performed a systematic review and
meta-analysis of 13 studies (1,180 patients) to assess the prog-
nostic role of MTV and TLG before treatment. The authors
found that high values of both volumetric parameters correlat-
ed significantly with a worse outcome. The pooled HRs for
OS were 3.51 (95% CI 2.62–4.72, p < 0.00001) and 3.14
(95% CI 2.24 – 4.40, p < 0.00001) for MTVand TLG, respec-
tively. However, the generalizability of these results is open to
question. First, loose criteria were followed in the literature
search strategy and inclusion of articles. Second, for both pa-
rameters no threshold values portending a worse outcome
were defined, thus preventing further analysis of the data.
In a prospective study in 77 patients affected by stage II–IV
HNSCC, Schinagl et al. [52] consistently applied five different
segmentation methods for coregistered CT and FDG PET scansTa
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at baseline. Among the different metrics obtained, only the gross
tumour volume (GTV) visually delineated on FDG PET images
was significantly correlated with outcome in oral cavity and
oropharyngeal tumours, while all isocontour-based volumes,
SUVmean and SUVmax, were not. A large single-centre [38] ret-
rospective study on 287 patients receiving IMRT-based treatment
Fig. 3 Impact of pretreatment
SUVmax on overall survival
Fig. 2 Impact of pretreatment
MTVon overall survival
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showed different results. In a univariate analysis, increasing
values of SUVmax (as a logarithmic variable) yielded a HR of
1.72 (95%CI 1.34–2.19) for a worse disease-free survival (DFS)
and OS. Multivariate analysis showed an additive effect of
increasing GTV (HR 1.74, 95% CI 1.33–2.27; increase in inter-
quartile range from 25% to 75% corresponding to an increase in
GTV from 27.4 cm3 to 95.8 cm3) and increasing SUVmax (HR
1.34, 95% CI 1.01–1.77; increase in interquartile range from
Fig. 5 Impact of pretreatment
SUVmax on progression-free
survival
Fig. 4 Impact of pretreatment
MTVon progression-free survival
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25% to 75% corresponding to an increase in SUVmax from 9.6 to
16.8) for a worse prognosis.
The link between FDG avidity and tumour volume has been
further explored by different groups focusing on MTV. In this
regard, the correlative, prospective imaging study of the ran-
domized phase 3 RTOG 0522 trial [40] is noteworthy. Of the
whole sample of 940 patients enrolled, 74 from 19 different
centres provided both pretreatment and posttreatment FDG
PET scans, as mandated upon inclusion. A prespecified acqui-
sition imaging protocol was followed in all patients. Excellent
centralized interobserver agreement (intraclass correlation coef-
ficient ≥0.80) on semiquantitative metrics was reported. Based
Fig. 7 Impact of pretreatment
SUVmax on locoregional control
Fig. 6 Impact of pretreatment
MTVon locoregional control
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on voxels with a minimum of 40% SUVmax, baseline primary
MTV above the median was the strongest prognosticator of
worse LRC (HR 4.01, 95% CI 1.28–12.52, p = 0.2). Other ret-
rospective studies [23, 27, 37] have underlined the prognostic
value of baseline MTV, reporting different cut-off values as
most significant for a worse outcome (combined primary and
nodal MTV >40 ml, >20 ml and >18 ml correlating with worse
DFS [23], LRC and OS [27], and disease-specific survival [37],
respectively). The prognostic value of MTVanalysed as a con-
tinuous variable has also been reported.
In a single-centre retrospective analysis in 83 patients, Tang
et al. [53] found that an increase in primary baseline MTV of
17 ml (from the 25th to the 75th percentile) was associated with
a doubling of the risk of disease progression (p = 0.0002) and of
death (p = 0.0048). Of note, combined primary and nodal MTV
(as a continuous variable) was also associated with a shorter
PFS (HR 4.23, p < 0.0001; CI not reported) and OS (HR 3.21,
p < 0.0029; CI not reported) in the subgroup of 64 patients with
p16-positive oropharyngeal cancer. In a larger cohort of 122
patients with oropharyngeal cancer, Castelli et al. [45] assessed
whether the use of different absolute and relative thresholds of
SUVmax result in different discriminatory power ofMTV.Using
a 51% relative SUVmax threshold, combined primary and nodal
MTV was the only significant factor in a multivariate analysis
predicting OS (HR 1.43 per 10 ml, CI 1.23–1.65, p < 0.001)
and DFS (HR 1.43 per 10 ml;,CI 1.23–1.65, p = 0.03). The
optimal cut-off value for MTV 51% was 22.7 ml, which was
able to discriminate 2-year DFS with rates of 63.3% versus
32.9% and LRC with rates of 68% versus 35.3%.
The absence of a consensus methodology on VOI delinea-
tion is clearly a limitation when comparing different datasets
on the prognostic relevance of MTV, since no single optimal
cut-off value is recognized. In line with previous experience,
our data reinforce the prognostic role of pretreatment MTVas
the most informative semiquantitative metabolic feature. In
line with our search inclusion criteria, the patient population
analysed was extremely homogeneous (about 95% of the
whole sample size) in terms of disease stage, radiotherapy
technique used and schedule of concomitant chemoradiother-
apy. With all due limitations, our analysis provides further
evidence on the predominant impact of pretreatment MTV
on HNSCC outcome compared with all other available FDG
PET metrics. Further consideration of its role also as a predic-
tive biomarker may be generated by pattern-of-failure data
correlating baseline FDG PET and radiation dose distribution
in HNSCC. Due et al. [54] performed a retrospective analysis
in 304 HNSCC patients with the aim of correlating the pattern
of disease failure with FDG uptake on pretreatment PET
scans. By performing a deformable registration of CT scans
acquired at the time of recurrence with the planning PET/CT
scan, the authors showed that 96% of relapses (95% CI 86–
99%) occurred in the high-dose region. In addition, they found
that recurrence density was higher in the central part of the
target volume (p < 0.0001), with a significant correlation with
increasing FDG avidity (p = 0.036). In a smaller cohort of 44
patients enrolled in a prospective phase 2 trial, Leclerc et al.
[55] showed that all ten recurrences arose in areas receiving
>95% of the dose determined on PET-based plans. A similar
finding was reported by Mohamed et al. [56], who hypothe-
sized that a 1-cm margin in addition to the 50% SUVmax
isocontour on pretreatment FDG PET scans would cover the
majority of type A recurrences (according to the authors’ def-
inition, those that arise in the central high-dose area).
Once again, it has to be underlined that, among others, the
main limitations of FDG in HNSCC are its suboptimal specific-
ity and the large variability in segmentationmethods. Potentially,
it could be hypothesized that hypoxia PET [57] and diffusion-
weightedmagnetic resonance imaging [58]may bemore refined
imaging biomarkers in the field of HNSCC. However, conclu-
sive results on their prognostic impact have long been awaited,
mainly due to the lack of reproducibility and cost issues
preventing their adoption on a large scale. In our opinion FDG
PET will remain the most widespread functional imaging mo-
dality used in clinical practice for many years to come.
Conclusion
The absence of prognostic biomarkers is a critical limitation in
the management of locally advanced HNSCC. With all due lim-
itations, our analysis showed that MTV defined from pretreat-
ment FDG PET scans has the strongest impact on patient out-
come after standard concurrent chemoradiotherapy. Prospective
studies to corroborate this finding through standardized FDG
PET acquisition and segmentation methods are warranted.
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